-- オーストラリアン・クリニカル・ラボ(ASX:ACL)は、ミシェル・ラーブ=イヴァノフ氏がビクトリア州最高裁判所に提起した代表訴訟における主張を否定し、「徹底的に」弁護する方針であると、火曜日にオーストラリア証券取引所に提出した書類で明らかにした。 提出書類によると、この訴訟は、2022年7月15日以前に同社および/または子会社であるメドラボ・パソロジーの顧客であり、2022年2月にメドラボ・パソロジーが受けたサイバー攻撃によって個人情報が影響を受けた人々を代表して提起されたものである。 提出書類によれば、訴状は、オーストラリア消費者法違反の疑いに基づき、被害を受けた個人に対する損害賠償を求めている。
Related Articles
Huadian New Energy 2025 Profit Down 18%, Revenue Up 15%
Huadian New Energy (SHA:600930) posted 2025 attributable net profit of 7.26 billion yuan, down 18% from 8.83 billion yuan the previous year.Earnings per share slipped to 0.18 yuan from 0.24 yuan, according to a filing with the Shanghai bourse.Operating revenue rose 15% year over year to 39.0 billion yuan from 34.0 billion yuan.Shares of the power company were down 1% in recent trade.
National Storage REIT Says New South Wales Court Approves Brookfield, GIC Takeover Scheme
National Storage REIT (ASX:NSR) confirmed that the Supreme Court of New South Wales has approved the share scheme of arrangement and granted judicial advice for the trust scheme, enabling a Brookfield Funds and GIC-led consortium to proceed with the acquisition of all the company stapled securities, according to a Tuesday Australian bourse filing.The schemes are now legally effective following lodgment with the Australian Securities and Investments Commission, and the company's securities are expected to be suspended from trading at the close of trading on Tuesday, per the filing.The scheme record date is April 29, with implementation scheduled for May 8, when security holders will receive the scheme consideration, the filing added.
Starpharma Says US FDA Supports First-in-Human Study of Cancer Radiotherapy Candidate; Shares Gain 7%
Starpharma Holdings (ASX:SPL) has received positive feedback from the US Food and Drug Administration (FDA) on the proposed design of its first-in-human phase 1 clinical study of the DEP HER2 radiotherapy candidate, according to a Tuesday filing with the Australian bourse.The company is developing the candidate to treat certain gastric/gastro-oesophageal junction cancers and other advanced cancers in patients who have previously received targeted therapy.The US FDA feedback supports plans to launch the phase one study, which is on track to begin in the second half of the year.The FDA also confirmed that the radiotherapy candidate is targeting a population with a significant unmet medical need, indicating the potential for a fast-track designation or other accelerated development pathways, Starpharma said.The company's shares were 7% higher in recent Tuesday trade.